These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 1426659)

  • 1. Immunotherapeutic strategies for neoplasia.
    Talmadge JE
    Dev Biol Stand; 1992; 77():17-28. PubMed ID: 1426659
    [No Abstract]   [Full Text] [Related]  

  • 2. Development of immunotherapeutic strategies for the treatment of malignant neoplasia.
    Talmadge JE
    Pathol Immunopathol Res; 1989; 8(5-6):250-75. PubMed ID: 2699034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological response modifiers (BRM), chemotherapy, and activated cytotoxic leukocyte subsets: strategies for rational design of apheresis-based cancer immunotherapies.
    Stevenson HC; Klein HG
    Prog Clin Biol Res; 1990; 337():559-65. PubMed ID: 2353018
    [No Abstract]   [Full Text] [Related]  

  • 4. [Ways to overcome the contradictions between the experimental and clinical chemotherapy of tumors].
    Syrkin AB
    Vopr Onkol; 1990; 36(6):740-4. PubMed ID: 2378096
    [No Abstract]   [Full Text] [Related]  

  • 5. Biological response modifiers: preclinical and clinical results.
    Talmadge JE; Clark J
    Cancer Chemother Biol Response Modif; 1987; 9():454-72. PubMed ID: 3079413
    [No Abstract]   [Full Text] [Related]  

  • 6. Biological response modifiers.
    Clark JW
    Cancer Chemother Biol Response Modif; 1988; 10():434-59. PubMed ID: 3079394
    [No Abstract]   [Full Text] [Related]  

  • 7. Dose intensity versus total dose of chemotherapy: an experimental basis.
    Skipper HE
    Important Adv Oncol; 1990; ():43-64. PubMed ID: 2182523
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunotoxin therapy of malignancy.
    Grossbard ML; Nadler LM
    Important Adv Oncol; 1992; ():111-35. PubMed ID: 1582669
    [No Abstract]   [Full Text] [Related]  

  • 9. Perfluorochemical emulsions: oxygen breathing in radiation sensitization and chemotherapy modulation.
    Teicher BA; Herman TS; Frei E
    Important Adv Oncol; 1992; ():39-59. PubMed ID: 1582677
    [No Abstract]   [Full Text] [Related]  

  • 10. Cancer therapy with combinations of biological response modifiers and cytotoxics: an update.
    Borden EC; Creekmore SP
    Cancer Cells; 1990 Jul; 2(7):217-20. PubMed ID: 2204387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant chemotherapy--clinical trials and laboratory models.
    Wittes RE
    Cancer Treat Rep; 1986 Jan; 70(1):87-103. PubMed ID: 3510738
    [No Abstract]   [Full Text] [Related]  

  • 12. [Strategies for studies on mechanism of action of antineoplastic agents].
    Kuśnierczyk H
    Postepy Hig Med Dosw; 1995; 49(1):85-96. PubMed ID: 8657622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical test methods for antitumor drugs in the U.S.S.R.
    Garin AM; Lichinitser MR
    Natl Cancer Inst Monogr; 1977 Mar; (45):227-33. PubMed ID: 337153
    [No Abstract]   [Full Text] [Related]  

  • 14. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
    Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
    Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolated limb perfusion with high-dose tumor necrosis factor for extremity melanoma and sarcoma.
    Fraker DL; Alexander HR
    Important Adv Oncol; 1994; ():179-92. PubMed ID: 8206489
    [No Abstract]   [Full Text] [Related]  

  • 16. Preclinical and clinical experience with cisplatin resistance.
    Marshall JL; Andrews PA
    Hematol Oncol Clin North Am; 1995 Apr; 9(2):415-29. PubMed ID: 7642471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer.
    Tahara H; Lotze MT
    Gene Ther; 1995 Mar; 2(2):96-106. PubMed ID: 7719935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assays for in vitro and in vivo synergy.
    Teicher BA
    Methods Mol Med; 2003; 85():297-321. PubMed ID: 12710216
    [No Abstract]   [Full Text] [Related]  

  • 19. Interventions that induce modifications in the tumor microenvironment.
    Bernhard EJ
    Cancer Radiother; 2011 Aug; 15(5):376-82. PubMed ID: 21571567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances and challenges in the use of biomarkers in clinical trials.
    Chabner B
    Clin Adv Hematol Oncol; 2008 Jan; 6(1):42-3. PubMed ID: 18322440
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.